FAP
MCID: ADN021
MIFTS: 70

Adenomatous Polyposis Coli (FAP) malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Eye diseases, Gastrointestinal diseases, Skin diseases, Fetal diseases, Bone diseases

Aliases & Classifications for Adenomatous Polyposis Coli

About this section
Sources:
12diseasecard, 24GeneTests, 27GTR, 31ICD10 via Orphanet, 37MedGen, 40MESH via Orphanet, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Adenomatous Polyposis Coli:

Name: Adenomatous Polyposis Coli 52 12 68
Gardner Syndrome 52 48 24 54 68
Brain Tumor-Polyposis Syndrome 2 52 27 68
Familial Adenomatous Polyposis 1 52 27
Familial Adenomatous Polyposis 54 70
Gardner's Syndrome 48 27
Fap 54 70
Polyposis Coli and Multiple Hard and Soft Tissue Tumors 48
Apc-Related Attenuated Familial Adenomatous Polyposis 54
 
Intestinal Polyposis, Osteomas, Sebaceous Cysts 48
Apc-Related Attenuated Familial Polyposis Coli 54
Colorectal Adenomatous Polyposis 54
Turcot Syndrome with Polyposis 54
Apc-Related Attenuated Fap 54
Familial Polyposis Coli 54
Gardners Syndrome 50
Apc-Related Afap 54

Characteristics:

Orphanet epidemiological data:

54
familial adenomatous polyposis:
Inheritance: Autosomal dominant,Autosomal recessive; Prevalence: 1-9/100000 (Europe),1-5/10000 (Denmark),1-9/100000 (Denmark),1-9/100000 (Sweden),1-5/10000 (Finland),1-9/100000 (Finland),1-5/10000 (United Kingdom),1-9/100000 (United Kingdom),1-9/1000000 (Australia),1-9/100000 (Australia); Age of onset: Adult; Age of death: adult
apc-related attenuated familial adenomatous polyposis:
Inheritance: Autosomal dominant,Autosomal recessive
turcot syndrome with polyposis:
Inheritance: Autosomal dominant; Age of onset: All ages

HPO:

64
adenomatous polyposis coli:
Inheritance: autosomal dominant inheritance
Onset and clinical course: variable expressivity

Classifications:



External Ids:

OMIM52 175100
MESH via Orphanet40 D011125, D005736
ICD10 via Orphanet31 D12.6
UMLS via Orphanet69 C0032580, C0017097

Summaries for Adenomatous Polyposis Coli

About this section
NIH Rare Diseases:48 Gardner syndrome is a form of familial adenomatous polyposis (fap) that is characterized by multiple colorectal polyps and various types of tumors, both benign (noncancerous) and malignant (cancerous). people affected by gardner syndrome have a high risk of developing colorectal cancer at an early age. they are also at an increased risk of developing other fap-related cancers, such as those of the small bowel, stomach, pancreas, thyroid, central nervous system, liver, bile ducts, and/or adrenal gland. other signs and symptoms of gardner syndrome include dental abnormalities; osteomas (benign bone growths); various skin abnormalities such as epidermoid cysts, fibromas (a benign tumor of the connective tissue), and lipomas; and desmoid tumors. it is caused by changes (mutations) in the apc gene and inherited in an autosomal dominant manner. although there is no cure for gardner syndrome, management options are available to reduce the risk of cancer. these may include high risk screening, prophylactic surgeries and/or certain types of medications. last updated: 1/14/2015

MalaCards based summary: Adenomatous Polyposis Coli, also known as gardner syndrome, is related to colorectal cancer and familial adenomatous polyposis, and has symptoms including abdominal pain, abdominal pain and diarrhea. An important gene associated with Adenomatous Polyposis Coli is APC (APC, WNT Signaling Pathway Regulator), and among its related pathways are Regulation of CDC42 activity and Nectin adhesion pathway. The drug celecoxib has been mentioned in the context of this disorder. Affiliated tissues include colon, skin and thyroid, and related mouse phenotypes are Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation and neoplasm.

OMIM:52 Familial adenomatous polyposis-1 is an autosomal dominant disorder characterized by predisposition to cancer. Affected... (175100) more...

UniProtKB/Swiss-Prot:70 Familial adenomatous polyposis: A cancer predisposition syndrome characterized by adenomatous polyps of the colon and rectum, but also of upper gastrointestinal tract (ampullary, duodenal and gastric adenomas). This is a viciously premalignant disease with one or more polyps progressing through dysplasia to malignancy in untreated gene carriers with a median age at diagnosis of 40 years.

Wikipedia:71 Adenomatous polyposis coli (APC) also known as deleted in polyposis 2.5 (DP2.5) is a protein that in... more...

Related Diseases for Adenomatous Polyposis Coli

About this section

Diseases related to Adenomatous Polyposis Coli via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 87)
idRelated DiseaseScoreTop Affiliating Genes
1colorectal cancer29.2APC, AXIN1, AXIN2, CDH1, CTNNB1, GSK3B
2familial adenomatous polyposis11.9
3samson gardner syndrome11.8
4attenuated familial adenomatous polyposis11.5
5mismatch repair cancer syndrome11.2
6mutyh-associated polyposis11.2
7colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas10.8
8desmoid disease, hereditary10.8
9duodenum cancer10.8
10soft tissue sarcoma10.8
11adenoma10.4
12breast cancer10.3
13macular degeneration, early-onset10.3APC, CTNNB1
14dfnb110.2APC, CTNNB1
15hepatocellular carcinoma10.2
16hepatocellular adenoma10.2
17squamous cell carcinoma10.2
18thyroiditis10.2
19lung cancer10.1
20colorectal adenoma10.1
21oral squamous cell carcinoma10.1
22neuronitis10.1
23diabetes mellitus, noninsulin-dependent, 210.1APC, CTNNB1
24autoimmune autonomic ganglionopathy10.1APC, AXIN2
25desmoid tumor10.1
26granulocytopenia10.1CDH1, CTNNB1
27familial hypopituitarism10.0APC, CDH1
28ideomotor apraxia10.0APC, CDH1, CTNNB1
29multicentric papillary thyroid carcinoma10.0AXIN1, AXIN2, CTNNB1
30retinoblastoma10.0
31hepatitis10.0
32ulcerative colitis10.0
33ameloblastoma10.0
34colitis10.0
35schizophrenia9.8
36medulloblastoma9.8
37parathyroid carcinoma9.8
38hepatitis c virus9.8
39adult t-cell leukemia9.8
40gastric cancer9.8
41hepatitis b9.8
42leukemia9.8
43colorectal adenocarcinoma9.8
44autism spectrum disorder9.8
45lymphoma9.8
46thrombosis9.8
47fourth cranial nerve palsy9.8
48sarcoma9.8
49myopia9.8
50esophagitis9.8

Graphical network of the top 20 diseases related to Adenomatous Polyposis Coli:



Diseases related to adenomatous polyposis coli

Symptoms & Phenotypes for Adenomatous Polyposis Coli

About this section

Symptoms by clinical synopsis from OMIM:

175100

Clinical features from OMIM:

175100

Human phenotypes related to Adenomatous Polyposis Coli:

 54 64 (show all 30)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm54 Frequent (79-30%)
2 colon cancer64 54 Frequent (79-30%) HP:0003003
3 multiple gastric polyps64 54 Very frequent (99-80%) HP:0004394
4 delayed eruption of teeth54 Occasional (29-5%)
5 multiple lipomas64 54 Occasional (29-5%) HP:0001012
6 duodenal polyposis64 54 Very frequent (99-80%) HP:0004783
7 adenomatous colonic polyposis64 54 Very frequent (99-80%) HP:0005227
8 irregular hyperpigmentation54 Occasional (29-5%)
9 fibroma54 Occasional (29-5%)
10 odontoma64 54 Occasional (29-5%) HP:0011068
11 increased number of teeth64 54 Occasional (29-5%) HP:0011069
12 neoplasm of the central nervous system54 Occasional (29-5%)
13 sarcoma54 Occasional (29-5%)
14 carious teeth64 HP:0000670
15 unerupted tooth64 HP:0000706
16 hyperpigmentation of the skin64 HP:0000953
17 hepatoblastoma64 HP:0002884
18 medulloblastoma64 HP:0002885
19 papillary thyroid carcinoma64 HP:0002895
20 small intestine carcinoid64 HP:0006722
21 adrenocortical carcinoma64 HP:0006744
22 duodenal adenocarcinoma64 HP:0006771
23 congenital hypertrophy of retinal pigment epithelium64 HP:0007649
24 adrenocortical adenoma64 HP:0008256
25 astrocytoma64 HP:0009592
26 keloids64 HP:0010562
27 fibroadenoma of the breast64 HP:0010619
28 desmoid tumors64 HP:0100245
29 osteoma64 HP:0100246
30 epidermal cyst64 HP:0200040

UMLS symptoms related to Adenomatous Polyposis Coli:


abdominal pain, diarrhea

GenomeRNAi Phenotypes related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00016-A8.7APC, AXIN1, AXIN2, GSK3B

MGI Mouse Phenotypes related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

41 (show all 12)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.9APC, CDH1, CTNNB1, MYC, SPATA13
2MP:00053718.6AMER1, APC, AXIN1, AXIN2, CTNNB1, MYC
3MP:00030128.2APC, AXIN2, CDH1, CTNNB1, GSK3B, MYC
4MP:00053828.1AMER1, APC, AXIN1, AXIN2, CTNNB1, GSK3B
5MP:00053808.0AMER1, APC, AXIN1, AXIN2, CDH1, CTNNB1
6MP:00053818.0APC, AXIN1, CDH1, CTNNB1, GSK3B, MYC
7MP:00053897.9APC, APC2, AXIN1, AXIN2, CDH1, CTNNB1
8MP:00053907.9AMER1, APC, AXIN1, AXIN2, CTNNB1, GSK3B
9MP:00053847.7AMER1, APC, APC2, AXIN1, AXIN2, CDH1
10MP:00028737.4APC, AXIN1, AXIN2, CDH1, CTNNB1, GSK3B
11MP:00053787.2AMER1, APC, APC2, AXIN1, AXIN2, CDH1
12MP:00053856.8AMER1, APC, AXIN1, AXIN2, CDH1, CTNNB1

Drugs & Therapeutics for Adenomatous Polyposis Coli

About this section

Drugs for Adenomatous Polyposis Coli (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 84)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Erythromycinapproved, vet_approvedPhase 499114-07-812560
Synonyms:
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
,10-dione
114-07-8
3''-O-demethylerythromycin
374700-25-1
45673_FLUKA
45674_FLUKA
79235-06-6
82343-12-2
A/T/S
AC-12744
AC1L1FIQ
AC1L1QK7
AC1L1ZUR
AC1O8PVA
AC1Q2UA1
AC1Q6O1S
AI3-50138
AR-1A4414
AR-1H0723
Abboticin
Abomacetin
Acneryne
Acnesol
Ak-Mycin
Ak-mycin
Akne Cordes Losung
Akne-Mycin
Akne-mycin (TN)
Aknederm Ery Gel
Aknemycin
Aknin
AustriaS
BB_NC-1332
BIDD:GT0017
BPBio1_000312
BSPBio_000282
BSPBio_002480
Benzamycin
Benzamycin Pak
Bristamycin
C-Solve-2
C01912
C37H67NO13
CCRIS 9078
CHEBI:42355
CHEMBL532
CID12560
CID3255
CID6713919
CID8233
D00140
DB00199
Del-Mycin
Derimer
Deripil
DivK1c_000294
DivK1c_000397
DivK1c_000702
Dotycin
Dumotrycin
E- mycin, Erycin, Robimysin
E-Base
E-Base (base)
E-Glades
E-Mycin
E-Mycin (base)
E-Solve 2
E0751
E0774_SIAL
E5389_SIGMA
E6376_SIAL
E7904_SIGMA
EINECS 204-040-1
EM
EMU
ERY
ERYC
ERYC (base)
ERYTHROMYCIN STEARATE
ETS
Emgel
Emu-V
Emu-Ve
Emuvin
Emycin
Endoeritrin
Erecin
Erimycin-T
Erisone
Eritomicina
Eritrocina
Eritromicina
Eritromicina [INN-Spanish]
Ermycin
Eros
Ery-B
Ery-Diolan
Ery-Sol
Ery-Tab
Ery-Tab (base)
Ery-maxin
Eryacne
Eryacnen
Eryc
Eryc (TN)
Eryc 125
Eryc Sprinkles
Eryc-125
Eryc-250
Erycen
Erycette
Erycin
Erycinum
Eryderm
Erydermer
Erygel
Erygel (TN)
Eryhexal
Erymax
Erymed
Erypar
Erysafe
Erytab
Erythra-Derm
Erythro
Erythro-Statin
Erythro-Teva
Erythrocin
Erythrocin Stearate
Erythroderm
Erythrogran
Erythroguent
Erythromast 36
Erythromid
Erythromycin
Erythromycin & VRC3375
Erythromycin (JP15/USP/INN)
 
Erythromycin A
Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279
Erythromycin B
Erythromycin C
Erythromycin Lactate
Erythromycin Ointment
Erythromycin Stearate
Erythromycin [INN:BAN:JAN]
Erythromycin base
Erythromycin estolate
Erythromycin ethylsuccinate
Erythromycin glucoheptonate
Erythromycin intravenous
Erythromycin lactobionate
Erythromycin oxime
Erythromycin sodium lauryl sulfate
Erythromycin, compd. with monododecyl sulfate, sodium salt
Erythromycine
Erythromycine [INN-French]
Erythromycinum
Erythromycinum [INN-Latin]
Erytop
Erytrociclin
Ethril 250
HMS1568O04
HMS1920M04
HMS2091D05
HMS500O16
HSDB 3074
I06-0245
IDI1_000294
IDI1_000397
IDI1_000702
Ilocaps
Ilosone
Ilosone (estolate)
Iloticina
Ilotycin
Ilotycin Gluceptate
Ilotycin T.S
Ilotycin T.S.
Inderm
Inderm Gel
IndermRetcin
KBio1_000294
KBio1_000397
KBio1_000702
KBio2_000555
KBio2_001139
KBio2_003123
KBio2_003707
KBio2_005691
KBio2_006275
KBioGR_001175
KBioSS_000555
KBioSS_001139
KST-1A8261
Kesso-Mycin
LMPK04000006
LS-187077
LS-64648
Latotryd
Lederpax
MLS001066618
Mephamycin
Mercina
MolPort-000-772-161
MolPort-002-507-378
MolPort-003-933-429
N-Methylerythromycin A
NCGC00179619-01
NCI-C55674
NINDS_000294
NINDS_000397
NINDS_000702
NSC 55929
NSC55929
Oftalmolosa Cusi Eritromicina
Oftamolets
PCE Dispertab (base)
Paediathrocin
Pantoderm
Pantodrin
Pantomicina
Pce
Pce (TN)
Pfizer-e
Pharyngocin
Prestwick0_000151
Prestwick1_000151
Prestwick2_000151
Prestwick3_000151
Prestwick_205
Primacine
Propiocine
Proterytrin
R-P Mycin
Retcin
Robimycin
Romycin
SBB057401
SMP1_000119
SMR000544946
SPBio_000778
SPBio_001226
SPBio_002221
SPECTRUM1500280
STK249736
Sans-acne
Sansac
Serp-AFD
Skid Gel E
Spectrum2_000759
Spectrum2_001263
Spectrum4_000538
Spectrum5_001596
Spectrum_000115
Spectrum_000659
Staticin
Staticin (TN)
Stiemicyn
Stiemycin
Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin
T-Stat
T-stat (TN)
Taimoxin-F
Theramycin Z
Tiloryth
Tiprocin
Torlamicina
UNII-63937KV33D
Udima Ery Gel
Wemid
Wyamycin S
adecane-2,10-dione (non-preferred name)
bmse000664
erythro
erythromycin
nchembio.285-comp13
érythromycine
2
Celecoxibapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1444169590-42-52662
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC-4228
AC1L1E6K
AI-525
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
CPD000550473
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
Celecoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
Célécoxib
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
KBio2_000912
 
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
MLS001165684
MLS001195656
MLS001304708
Medicoxib
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC-58635
SC58635
SMR000550473
SPBio_001512
SPECTRUM1503678
Solexa
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
Spectrum_000432
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM-177
YM177
ZINC02570895
cMAP_000027
celecoxib
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
3Antirheumatic AgentsPhase 4, Phase 2, Phase 3, Phase 110956
4Cyclooxygenase 2 InhibitorsPhase 4, Phase 2, Phase 3, Phase 1624
5Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 2, Phase 3, Phase 14443
6Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 3, Phase 123689
7Anti-Bacterial AgentsPhase 4, Phase 2, Phase 111226
8Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 3, Phase 110729
9Cyclooxygenase InhibitorsPhase 4, Phase 2, Phase 3, Phase 12870
10Analgesics, Non-NarcoticPhase 4, Phase 2, Phase 3, Phase 16501
11Erythromycin EstolatePhase 499
12Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 122062
13Erythromycin EthylsuccinatePhase 499
14Erythromycin stearatePhase 499
15AnalgesicsPhase 4, Phase 2, Phase 3, Phase 111733
16Gastrointestinal AgentsPhase 4, Phase 2, Phase 38402
17
Ursodeoxycholic acidapproved, investigationalPhase 2, Phase 397128-13-231401
Synonyms:
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oate
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oic acid
(3a,5b,7b)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid
(3α,5β,7β)-3,7-dihydroxycholan-24-oic acid
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
128-13-2
17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol
3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid
3,7-Dihydroxycholan-24-oic acid
3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid
3-alpha,7-beta-Dihydroxycholanic acid
3-alpha,7-beta-Dioxycholanic acid
3a,7b-Dihydroxy-5b-cholan-24-oate
3a,7b-Dihydroxy-5b-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholanic acid
4-10-00-01604 (Beilstein Handbook Reference)
50809-41-1
5beta-Cholan-24-oic acid-3alpha,7beta-diol
5beta-Cholanic Acid-3alpha,7beta-diol
7-beta-Hydroxylithocholic acid
7beta-Hydroxylithocholic acid
80225-86-1
AB00513977
AC-18919
AC-2081
AC1L1LJH
Acide ursodesoxycholique
Acide ursodesoxycholique [INN-French]
Acido ursodeossicolico
Acido ursodeossicolico [Italian]
Acido ursodeoxicolico
Acido ursodeoxicolico [INN-Spanish]
Acidum ursodeoxycholicum
Acidum ursodeoxycholicum [INN-Latin]
Actigall
Actigall (TN)
Antigall
Arsacol
BB_NC-2372
BPBio1_001052
BRN 3219888
BSPBio_000956
C07880
C24H40O4
CCRIS 5502
CHEBI:9907
CHEMBL1551
CHEMBL73390
CID11516715
CID31401
CPD-10534
CPD000058403
Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)- (9CI)
Cholit-ursan
D00734
DB01586
Delursan
Deoxyursocholic Acid
Destolit
Deursil
Dom-ursodiol c
EINECS 204-879-3
HMS1570P18
 
ISO-URSODEOXYCHOLIC ACID
IU5
LMST04010033
LS-53033
Litursol
Lyeton
MLS000028461
MLS001066373
MolPort-001-794-630
MolPort-005-932-884
NCGC00179363-01
NCI60_028904
NSC 657950
NSC 683769
PHL-ursodiol c
PMS-ursodiol c
Peptarom
Prestwick0_000958
Prestwick1_000958
Prestwick2_000958
Prestwick3_000958
S1643_Selleck
SAM002264653
SMP2_000012
SMR000058403
SPBio_003105
Sodium Ursodeoxycholate
Solutrat
U-9000
U0030
U5127_SIGMA
UDCA
UDCS
UNII-724L30Y2QR
URSODEOXYCHOLIC ACID
UrSO
Urosdesoxycholate
Urosdesoxycholic acid
Urosiol
Ursacholic Acid
Ursacol
Urso
Urso (TN)
Urso 250
Urso DS
Urso Forte
Ursobilin
Ursochol
Ursodamor
Ursodeoxy cholic acid
Ursodeoxycholate
Ursodeoxycholic acid
Ursodeoxycholic acid (JP15/INN)
Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol
Ursodeoxycholicacid
Ursodesoxycholic acid
Ursodexycholate
Ursodexycholic Acid
Ursodexycholic acid
Ursodiol
Ursodiol (USP)
Ursodiol [USAN]
Ursofalk
Ursolvan
Ursosan
chenodeoxycholic acid
ursodeoxycholate
ursodiol
18
SulindacapprovedPhase 3, Phase 23738194-50-25352, 1548887
Synonyms:
(E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-((P-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid
2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
32004-68-5
38194-50-2
5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid
53933-60-1
6301-55-9
9000-14-0
AB00513800
AC-4550
AC1L1K5T
AC1LU7GU
AC1LU7GY
AC1Q6YHK
AKOS004119989
AR-1A9609
Aclin
Aflodac
Alphapharm Brand of Sulindac
Apo Sulin
Apo-Sulin
Apotex Brand of Sulindac
Arthrobid
Arthrocine
BB_SC-1128
BPBio1_000315
BRD-A03427350-001-01-3
BRD-A13946108-001-04-9
BRN 2951842
BSPBio_000285
BSPBio_002890
C01531
C20H17FO3S
CAS-38194-50-2
CCRIS 3305
CHEBI:9352
CHEMBL1376
CID1548885
CID1548887
CID5352
CPD000326718
Cahill May Roberts Brand of Sulindac
Chemia Brand of Sulindac
Chibret
Clinoril
Clinoril (TN)
Copal
Copal resin
Copal rosin varnish
Copals
D00120
D013467
DB00605
DivK1c_000601
EINECS 232-527-9
EINECS 250-893-8
EINECS 253-819-2
EINECS 258-873-0
EU-0101070
Gum copal
HMS1568O07
HMS1921C11
HMS2089J04
HMS2092K15
HMS501O03
I06-0523
IDI1_000601
KBio1_000601
KBio2_001506
KBio2_002320
KBio2_004074
KBio2_004888
KBio2_006642
KBio2_007456
KBio3_002110
KBio3_002800
KBioGR_001571
 
KBioGR_002320
KBioSS_001506
KBioSS_002322
KST-1B6530
Kenalin
Kendrick Brand of Sulindac
Klinoril
LS-81610
Lopac-S-8139
Lopac0_001070
MK 231
MK-231
MK231
MLS001056554
MLS001304027
MLS002207124
Merck Brand of Sulindac
Merck Sharp & Dohme Brand of Sulindac
Mobilin
MolPort-002-507-760
MolPort-003-666-287
NCGC00015970-01
NCGC00015970-02
NCGC00015970-03
NCGC00015970-08
NCGC00025268-01
NCGC00025268-02
NCGC00025268-03
NCGC00094349-01
NCGC00094349-02
NINDS_000601
Novo Sundac
Novo-Sundac
Novopharm Brand of Sulindac
Nu Pharm Brand of Sulindac
Nu Sulindac
Nu-Pharm Brand of Sulindac
Nu-Sulindac
Prestwick0_000073
Prestwick1_000073
Prestwick2_000073
Prestwick3_000073
Prestwick_456
Resin copal
S 8139
S2007_Selleck
S4429_SIAL
S8139_SIAL
S8139_SIGMA
SAM002554933
SBB058181
SMR000043852
SMR000326718
SPBio_001451
SPBio_002206
SPECTRUM1500556
STK802068
Spectrum2_001326
Spectrum3_001365
Spectrum4_000876
Spectrum5_001024
Spectrum_001026
Sulindac
Sulindac (JAN/USP/INN)
Sulindac [USAN:BAN:INN:JAN]
Sulindac sulfoxide
Sulindaco
Sulindaco [INN-Spanish]
Sulindacum
Sulindacum [INN-Latin]
Sulindal
Tocris-1707
UNII-184SNS8VUH
UNII-M5221THD3M
UNM-0000306136
Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid
[(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid
cMAP_000021
cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
cis-5-Fluoro-2-methyl-1-((P-methylsulfinyl)benzylidene)indene-3-acetic acid
cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid
sulindac
{(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid
{(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid
{5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid
19
LoperamideapprovedPhase 314553179-11-63955
Synonyms:
2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
34552-83-5 (mono-hydrochloride)
4-(4-Chlorophenyl)-N,N-dimethyl-.alpha.,.alpha.-diphenyl-4-hydroxy-1-piperidinebutanamide
4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
5-21-02-00379 (Beilstein Handbook Reference)
53179-11-6
AB00053697
AC1L1H38
AKOS000573892
Apo-Loperamide
BAS 01889668
BPBio1_000274
BRD-K61250553-001-02-9
BRD-K61250553-003-05-8
BRN 1558273
BSPBio_000248
BSPBio_001381
BSPBio_002769
Bio1_000082
Bio1_000571
Bio1_001060
Bio2_000101
Bio2_000581
C07080
C29H33ClN2O2
CAS-34552-83-5
CBiol_001796
CHEBI:162259
CHEBI:6532
CHEMBL841
CID3955
D08144
DB00836
Diamide (TN)
Diarr-Eze
DivK1c_000215
EINECS 258-416-5
HMS1791F03
HMS1989F03
HMS2089C13
IDI1_000215
IDI1_033851
Imodium A-D
Imodium A-D Caplets
Ioperamide
KBio1_000215
KBio2_000101
KBio2_000854
KBio2_002669
KBio2_003422
KBio2_005237
KBio2_005990
KBio3_000201
 
KBio3_000202
KBio3_001989
KBioGR_000101
KBioGR_001685
KBioSS_000101
KBioSS_000854
Kaopectate II
L000709
LS-114352
Lopac-L-4762
Lopac0_000708
Loperacap
Loperamid
Loperamida
Loperamida [INN-Spanish]
Loperamide (INN)
Loperamide Monohydrochloride
Loperamide [INN:BAN]
Loperamide hydrochloride
Loperamidum
Loperamidum [INN-Latin]
Lopéramide
Maalox Anti-Diarrheal
MolPort-001-969-016
NCGC00015608-01
NCGC00015608-08
NCGC00016828-01
NCGC00024818-01
NCGC00024818-02
NCGC00024818-03
NCGC00024818-04
NCGC00024818-05
NINDS_000215
Nu-Loperamide
Oprea1_109220
PMS-Loperamide
Pepto Diarrhea Control
Prestwick0_000144
Prestwick1_000144
Prestwick2_000144
Prestwick3_000144
R-18553
Rho-Loperamide
SPBio_001816
SPBio_002187
ST095179
Spectrum2_001738
Spectrum3_001015
Spectrum4_001143
Spectrum5_001374
Spectrum_000374
Tocris-0840
UNII-6X9OC3H4II
loperamide
nchembio.559-comp8
nchembio.79-comp7
20DolutegravirapprovedPhase 31501051375-16-654726191
21Cholagogues and CholereticsPhase 2, Phase 3130
22Antiviral AgentsPhase 39967
23AntibodiesPhase 36394
24ImmunoglobulinsPhase 36394
25AntidiarrhealsPhase 3145
26Antiprotozoal AgentsPhase 3, Phase 22051
27Antiparasitic AgentsPhase 3, Phase 22199
28Protective AgentsPhase 2, Phase 37443
29HIV Integrase InhibitorsPhase 3397
30Integrase InhibitorsPhase 3418
31Antibodies, MonoclonalPhase 34039
32Anti-HIV AgentsPhase 33162
33Anti-Retroviral AgentsPhase 33296
34ColaNutraceuticalPhase 2, Phase 3, Phase 11946
35Omega 3 Fatty AcidNutraceuticalPhase 2, Phase 31018
36
OrnithineNutraceuticalPhase 3, Phase 2713184-13-26262, 389
Synonyms:
(+)-S-Ornithine
(+/-)-2,5-Diaminopentanoic acid monohydrochloride
(S)-2,5-Diaminopentanoate
(S)-2,5-Diaminopentanoic acid
(S)-Ornithine
(S)-a,D-Diaminovalerate
(S)-a,D-Diaminovaleric acid
2,5-Diaminopentanoic acid hydrochloride
5-Amino-L-Norvaline
D -2,5-Diaminopentanoic acid
D-Ornithine
DL -2,5-Diaminopentanoic acid
DL-ornithine
DL-ornithine HCL
DL-ornithine monohydrochloride
DL-ornithine, hydrochloride
 
L -2,5-Diaminopentanoic acid
L-(-)-Ornithine
L-Ornithine
L-Ornithine hydrochloride
L-Ornithine hydrochloride (van)
L-Ornithine monohydrochloride
L-Ornithine, monohydrochloride
L-Ornithine-carboxy-14C hydrochloride
MonohydrochlorideDL-Ornithine
Monohydrochloridel-Ornithine
Ornithine DL-form HCL
Ornithine DL-form monohydrochloride
Ornithine hydrochloride
Ornithine hydrochloride (van)
Ornithine monohydrochloride
Ornithine, hydrochloride (1:1)
Ornithine, monohydrochloride
Poly-L-ornithine hydrochloride
37
MetforminapprovedPhase 21803657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
38
Miconazoleapproved, investigational, vet_approvedPhase 2, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
39
EverolimusapprovedPhase 2, Phase 11940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
40
Sirolimusapproved, investigationalPhase 2, Phase 1194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
41
Inulinapproved, nutraceuticalPhase 21069005-80-524763
Synonyms:
(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethy
189444-25-5
887747-94-6
AC1L2NNM
AI3-19506
CID24763
DB00638
 
EINECS 232-684-3
INULIN
Inulin USP 27
Inulin [BAN]
Inulin and sodium chloride
Inulin from Jerusalem artichokes
LS-186416
LS-187349
42
Vitamin Aapproved, nutraceutical, vet_approvedPhase 249211103-57-4, 68-26-8445354
Synonyms:
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
.alpha.lin
.alpha.sterol
.beta.-Retinol
11103-57-4
13123-33-6
1341-18-0
1406-67-3
17104-91-5
1rbp
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer
4-06-00-04133 (Beilstein Handbook Reference)
53637-36-8
5979-23-7
68-26-8
95144_FLUKA
95144_SIGMA
95146_FLUKA
95146_SIGMA
A-Mulsal
A-Sol
A-Vi-Pel
A-Vitan
AC-11701
AC1L9HU3
AC1Q7BU9
ACON
ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1)
AR-1L3057
ATAV
Afaxin
Agiolan
Agoncal
Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol
Alcovit A
All Trans Retinol
All-trans retinol
All-trans-Retinol
Alphalin
Alphasterol
Anatola
Anatola A
Anti-infective vitamin
Antixerophthalmic vitamin
Antixerophthalmisches Vitamin
Aoral
Apexol
Apostavit
Aquasol A Parenteral
Aquasynth
Atars
Avibon
Avita
Avitol
Axerol
Axerophthol
Axerophtholum
BIDD:PXR0102
BRN 0403040
Bentavit A
Biosterol
C00473
C17276
C20H30O
CCRIS 5444
CHEBI:17336
CHEMBL986
CID445354
Chocola A
Cylasphere
D014801
D06543
DB00162
Del-VI-A
Disatabs Tabs
Dofsol
Dohyfral A
EINECS 200-683-7
EINECS 234-328-2
Epiteliol
HMS1921B04
HMS2092L13
HMS501I08
HSDB 815
Hi-A-Vita
Homagenets Aoral
Homagenets aorl
Hydrovit A
IDI1_000486
LMPR01090001
LPK
LS-1578
Lard Factor
M.V.C. 9+3
M.V.I.-12
 
MLS001066379
MLS001074751
MolPort-001-785-962
Mvc Plus
Myvpack
NCGC00091784-01
NCGC00091784-02
NCGC00091784-03
NCGC00091784-04
NCGC00091784-05
NCGC00091784-06
NSC 122759
NSC122759
Nio-A-Let
Oleovitamin A
Ophthalamin
Plivit A
Prepalin
R7632_SIGMA
Retin-11,12-t2-ol (9CI)
Retinol
Retinol [INN:BAN]
Retinol solution
Retinol, all-trans- (8CI)
Retinol-(cellular-retinol-binding-protein)
Retinolo
Retinolo [DCIT]
Retinolum
Retinolum [INN-Latin]
Retrovitamin A
Ro-a-vit
Rovimix A 500
SDCCGMLS-0066724.P001
SMP2_000102
SMR000112036
SPECTRUM1501203
ST057232
Sehkraft A
Solu-A
Spectrum5_000993
Spectrum5_001997
Super A
Testavol
Testavol S
Thalasphere
UNII-81G40H8B0T
UNII-G2SH0XKK91
Vaflol
Vafol
Veroftal
Vi-.alpha.
Vi-Alpha
Vi-Dom-A
Vi-a
Vio-A
Vitamin A
Vitamin A (Feed)
Vitamin A (USP)
Vitamin A alcohol
Vitamin A alcohol (VAN)
Vitamin A cryst
Vitamin A1
Vitamin A1 alcohol
Vitamin A1 alcohol, all trans
Vitamin- A
Vitamin- A alcohol
Vitamin- A alcohol solution
Vitamin- A1
Vitamin-?A
Vitamin-?A alcohol
Vitamin-?A alcohol solution
Vitamin-?A1
Vitamine A
Vitaminum A
Vitavel A
Vitavel-A
Vitpex
Vogan
Vogan-Neu
Vogan-nu
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1
Wachstumsvitamin
ZINC03831417
Zinosan N
[11,12-3H]-Retinol
alin
all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
all-trans-Retinol
all-trans-Retinyl alcohol
all-trans-Vitamin A
all-trans-Vitamin A alcohol
all-trans-Vitamin A1
all-trans-retinol
all-trans-retinyl alcohol
all-trans-vitamin A alcohol
b-Retinol
beta-Retinol
retinol
tROL
trans-Retinol
trans-Retinol acid (Vitamin A)
trans-Vitamin A alcohol
trans-retinol
43Hypoglycemic AgentsPhase 25896
44Turmeric extractPhase 276
45Protein Kinase InhibitorsPhase 23689
46
Erlotinib HydrochloridePhase 2810183319-69-9176871
Synonyms:
 
erlotinib hydrochloride
47
CurcuminPhase 2146458-37-7969516
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
C.I. Natural Yellow 3
CI Natural Yellow 3
Cucurmin
Curcuma
Curcumin
Curcumin I
Diferaloylmethane
Diferuloylmethane
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
Hydrastis
 
Indian saffron
Indian turmeric
Kacha haldi
Kurkumin [czech]
Merita earth
Natural yellow 3
Orange root
Safran D'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yo-kin
Zlut prirodni 3 [Czech]
48Retinol palmitatePhase 2492
49Immunosuppressive AgentsPhase 2, Phase 113086
50Antifungal AgentsPhase 2, Phase 13696

Interventional clinical trials:

(show top 50)    (show all 85)
idNameStatusNCT IDPhase
1Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous PolyposisUnknown statusNCT02175914Phase 4
2Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted VersionNot yet recruitingNCT02354560Phase 4
3A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)TerminatedNCT00140894Phase 4
4Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control PatientsTerminatedNCT00151476Phase 4
5Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) PatientsUnknown statusNCT00134758Phase 2, Phase 3
6Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPACompletedNCT00510692Phase 2, Phase 3
7Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous PolyposisCompletedNCT00808743Phase 2, Phase 3
8Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove PolypsCompletedNCT00005094Phase 3
9Clinical Approaches to Ileal Pouch DysfunctionCompletedNCT00293553Phase 3
10Australian Clinical Study of the Apnex Medical HGNS System to Treat Obstructive Sleep ApneaCompletedNCT01186926Phase 2, Phase 3
11Use of Post Operative Loperamide in Colorectal Patients After Diverting IleostomiesRecruitingNCT02263365Phase 3
12Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)Active, not recruitingNCT01483144Phase 3
13Compassionate Use of Ibalizumab for the Treatment of HIV InfectionNo longer availableNCT02028819Phase 3
14Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)TerminatedNCT00585312Phase 3
15Coxib-inhibition of Duodenal Polyp Growth in FAPTerminatedNCT00844727Phase 2, Phase 3
16A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)WithdrawnNCT01245816Phase 3
17Exisulind in Preventing Polyps in Patients With Familial Adenomatous PolyposisWithdrawnNCT00026468Phase 2, Phase 3
18Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous PolyposisUnknown statusNCT00319007Phase 2
19The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled StudyUnknown statusNCT01725490Phase 2
20Treatment for Presumed Ocular HistoplasmosisUnknown statusNCT01790893Phase 1, Phase 2
21A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis PatientsCompletedNCT01187901Phase 2
22Curcumin in Treating Patients With Familial Adenomatous PolyposisCompletedNCT00641147Phase 2
23Sirolimus and Familial Adenomatous Polyposis (FAP)RecruitingNCT03095703Phase 2
24A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type FibromatosisRecruitingNCT01265030Phase 1, Phase 2
25MLE4901 vs. Placebo for the Treatment of PCOSRecruitingNCT02865915Phase 2
26Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal CancersActive, not recruitingNCT00503035Phase 2
27Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon CancerNot yet recruitingNCT02961374Phase 2
28Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous Polyposis.Not yet recruitingNCT03061591Phase 2
29Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous PolyposisTerminatedNCT00033371Phase 2
30Outpatient Neutropenic Diet StudyTerminatedNCT00947648Phase 2
31Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis PatientsWithdrawnNCT00248053Phase 2
32Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CWCompletedNCT02113202Phase 1
33Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)CompletedNCT00770991Phase 1
34Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous PolyposisCompletedNCT00685568Phase 1
35A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy VolunteersCompletedNCT00813241Phase 1
36Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet ActionCompletedNCT02060396Phase 1
37Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard EndoscopyUnknown statusNCT00253812
38Chemoprevention of Gastric Cancer by Intervention With Helicobacter Pylori and Cyclooxygenase PathwayUnknown statusNCT00498134
39Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal CancerUnknown statusNCT00675636
40Is Diverting Ileostomy Necessary in Stapled Ileoanal Pouch?CompletedNCT01173250
41A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner SyndromeCompletedNCT01286662
42Dual Focus NBI and pCLE in FAP Related Duodenal AdenomaCompletedNCT02162173
43Genetic Analysis of Hereditary Prostate CancerCompletedNCT00001469
44Alcohol Intake, Alcohol Metabolizing Enzymes Gene Polymorphisms and the Risk of Colorectal CancerCompletedNCT03155542
45Endoscopic Papillectomy for Early Ampullary Tumors: Long-term Results of the First Large Multicenter Prospective StudyCompletedNCT01764503
46Oligogenic Determinism of Colorectal CancerCompletedNCT01057953
47Single Incision Laparoscopic Surgery in Treating Patients With Colorectal DiseaseCompletedNCT01656746
48Effects of Omega-3 Fatty Acids on Markers of InflammationCompletedNCT01129050
49Ingenio Device Algorithm StudyCompletedNCT01441583
50Effects of Raw Versus Other Milk Sources on Lactose DigestionCompletedNCT01129791

Search NIH Clinical Center for Adenomatous Polyposis Coli

Inferred drug relations via UMLS68/NDF-RT46:

Genetic Tests for Adenomatous Polyposis Coli

About this section

Genetic tests related to Adenomatous Polyposis Coli:

id Genetic test Affiliating Genes
1 Familial Adenomatous Polyposis 127
2 Gardner Syndrome27 24 APC
3 Brain Tumor-Polyposis Syndrome 227

Anatomical Context for Adenomatous Polyposis Coli

About this section

MalaCards organs/tissues related to Adenomatous Polyposis Coli:

36
Colon, Skin, Thyroid, Brain, Liver, Bone, Adrenal gland

Publications for Adenomatous Polyposis Coli

About this section

Articles related to Adenomatous Polyposis Coli:

(show top 50)    (show all 305)
idTitleAuthorsYear
1
Does adenomatous polyposis coli gene promoter 1A methylation increase non-small cell lung cancer risk? A meta-analysis. (28497891)
2017
2
A metabolic switch controls intestinal differentiation downstream of Adenomatous polyposis coli (APC). (28397687)
2017
3
Extracolonic cancer risk in Dutch patients with APC (adenomatous polyposis coli)-associated polyposis. (28490611)
2017
4
Insulin signaling regulates a functional interaction between Adenomatous Polyposis Coli (APC) and cytoplasmic dynein. (28057765)
2017
5
Association between Hepatitis C Virus Infection, p53 Phenotypes, and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas. (28203651)
2016
6
Adenomatous polyposis coli regulates radial axonal sorting and myelination in the PNS. (27226321)
2016
7
Characterization of Adenomatous Polyposis Coli Protein Dynamics and Localization at the Centrosome. (27144584)
2016
8
miR-582-5P induces colorectal cancer cell proliferation by targeting adenomatous polyposis coli. (27595705)
2016
9
Cribriform morular variant of papillary thyroid carcinoma: Cytomorphology, differential diagnosis and diagnostic implications in patients with adenomatous polyposis coli. (28028343)
2016
10
Tumour Suppressor Adenomatous Polyposis Coli (APC) localisation is regulated by both Kinesin-1 and Kinesin-2. (27272132)
2016
11
Copy number of the Adenomatous Polyposis Coli gene is not always neutral in sporadic colorectal cancers with loss of heterozygosity for the gene. (26970738)
2016
12
A novel pathogenic large germline deletion in adenomatous polyposis coli gene in a Chinese family with familial adenomatous polyposis. (27391059)
2016
13
Inactivation of Adenomatous Polyposis Coli Reduces Bile Acid/Farnesoid X Receptor Expression through Fxr gene CpG Methylation in Mouse Colon Tumors and Human Colon Cancer Cells. (26609171)
2016
14
Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer. (27798265)
2016
15
Adenomatous polyposis coli genotype-dependent toll-like receptor 4 activity in colon cancer. (26760960)
2016
16
Deep vein thrombosis in a patient of adenomatous polyposis coli treated successfully with aspirin: A case report. (27386068)
2016
17
ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli. (27334689)
2016
18
Analysing the mutational status of adenomatous polyposis coli (APC) gene in breast cancer. (27028212)
2016
19
Adenomatous polyposis coli (APC) regulates miR17-92 cluster through I^-catenin pathway in colorectal cancer. (26804172)
2016
20
MicroRNA-663 activates the canonical Wnt signaling through the adenomatous polyposis coli suppression. (26028359)
2015
21
Adenomatous polyposis coli mutants dominantly activate Hsf1-dependent cell stress pathways through inhibition of microtubule dynamics. (26320184)
2015
22
Association of CD24 and the adenomatous polyposis coli gene polymorphisms with oral lichen planus. (26187149)
2015
23
Tissue-Specific Effects of Reduced I^-catenin Expression on Adenomatous Polyposis Coli Mutation-Instigated Tumorigenesis in Mouse Colon and Ovarian Epithelium. (26528816)
2015
24
Adenomatous Polyposis Coli Protein Deletion in Efferent Olivocochlear Neurons Perturbs Afferent Synaptic Maturation and Reduces the Dynamic Range of Hearing. (26085645)
2015
25
Adenomatous polyposis coli (APC)-induced apoptosis of HT29 colorectal cancer cells depends on mitochondrial oxidative metabolism. (26004395)
2015
26
Mesenchymal adenomatous polyposis coli plays critical and diverse roles in regulating lung development. (26092405)
2015
27
Concurrent Hepsin overexpression and adenomatous polyposis coli deletion causes invasive prostate carcinoma in mice. (26139199)
2015
28
High-resolution Melting Analysis for Gene Scanning of Adenomatous Polyposis Coli (APC) Gene With Oral Squamous Cell Carcinoma Samples. (26447891)
2015
29
Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis. (26334567)
2015
30
Expression and mutation pattern of I^-catenin and adenomatous polyposis coli in colorectal cancer patients. (25660336)
2015
31
Adenomatous Polyposis Coli Mutation Leads to Myopia Development in Mice. (26495845)
2015
32
A novel pathogenic germline mutation in the adenomatous polyposis coli gene in a Chinese family with familial adenomatous coli. (26311738)
2015
33
Residual rectal mucosa after stapled vs. handsewn ileal J-pouch-anal anastomosis in patients with familial adenomatous polyposis coli (FAP)--a critical issue. (25586093)
2015
34
Two Chinese pedigrees for adenomatous polyposis coli: new mutations at codon 1309 and predisposition to phenotypic variations. (24664542)
2014
35
Low-grade neuroendocrine tumors arising in intestinal adenomas: evidence for alterations in the adenomatous polyposis coli/I^-catenin pathway. (25149552)
2014
36
Adenomatous polyposis coli (APC) membrane recruitment 3, a member of the APC membrane recruitment family of APC-binding proteins, is a positive regulator of Wnt-I^-catenin signalling. (24251807)
2014
37
Early postoperative complications after stapled vs handsewn restorative proctocolectomy with ileal pouch-anal anastomosis in 148 patients with familial adenomatous polyposis coli: a matched-pair analysis. (23941307)
2014
38
different Roles for the axin interactions with the SAMP versus the second twenty amino acid repeat of adenomatous polyposis coli. (24722208)
2014
39
Aspirin augments the expression of Adenomatous Polyposis Coli protein by suppression of IKKI^. (24613833)
2014
40
The effects of genistein and daidzein on cell proliferation kinetics in HT29 colon cancer cells: the expression of CTNNBIP1 (I^-catenin), APC (adenomatous polyposis coli) and BIRC5 (survivin). (24390805)
2014
41
5-Fluorouracil mediated anti-cancer activity in colon cancer cells is through the induction of Adenomatous Polyposis Coli: Implication of the long-patch base excision repair pathway. (25460919)
2014
42
Adenomatous polyposis coli gene large deletions in Iranian patients with familial adenomatous polyposis. (25494137)
2014
43
Minimal access laparoscopic surgery for treatment of ulcerative colitis and familial adenomatous polyposis coli in children and adolescents. (25247476)
2014
44
N-terminal truncation mutations of adenomatous polyposis coli are associated with primary cilia defects. (25150829)
2014
45
Anal transitional zone neoplasia in patients with familial adenomatous polyposis coli syndrome. (23739184)
2013
46
Ultrasensitive detection of unknown colon cancer-initiating mutations using the example of the Adenomatous polyposis coli gene. (24005794)
2013
47
Desmoid tumour biology in patients with familial adenomatous polyposis coli. (23334997)
2013
48
miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma. (23087084)
2013
49
Adenomatous polyposis coli gene involvement in ileal enterochromaffin cell neuroendocrine neoplasms. (24139208)
2013
50
Adenomatous polyposis coli-mediated accumulation of abasic DNA lesions lead to cigarette smoke condensate-induced neoplastic transformation of normal breast epithelial cells. (23555190)
2013

Variations for Adenomatous Polyposis Coli

About this section

UniProtKB/Swiss-Prot genetic disease variations for Adenomatous Polyposis Coli:

70 (show all 11)
id Symbol AA change Variation ID SNP ID
1APCp.Ser171IleVAR_005032
2APCp.Arg414CysVAR_005033rs137854567
3APCp.Ser784ThrVAR_005034
4APCp.Glu911GlyVAR_005038
5APCp.Pro1176LeuVAR_005044
6APCp.Thr1313AlaVAR_005051rs863225349
7APCp.Arg1348TrpVAR_005053
8APCp.Ser2621CysVAR_005056rs72541816
9APCp.Leu2839PheVAR_005057
10APCp.Ser722GlyVAR_009614
11APCp.Ala1184ProVAR_009616

Clinvar genetic disease variations for Adenomatous Polyposis Coli:

5 (show all 182)
id Gene Variation Type Significance SNP ID Assembly Location
1APCNM_ 000038.5(APC): c.1213C> T (p.Arg405Ter)SNVPathogenicrs587779780GRCh38Chr 5, 112819245: 112819245
2APCNM_ 000038.5(APC): c.2413C> T (p.Arg805Ter)SNVPathogenicrs587779783GRCh38Chr 5, 112838007: 112838007
3APCNM_ 000038.5(APC): c.3088A> T (p.Lys1030Ter)SNVPathogenicrs587779786GRCh38Chr 5, 112838682: 112838682
4APCNM_ 000038.5(APC): c.646C> T (p.Arg216Ter)SNVPathogenicrs62619935GRCh38Chr 5, 112792446: 112792446
5APCNM_ 000038.5(APC): c.5934_ 5937delAAAC (p.Asn1979Thrfs)deletionPathogenicrs587781330GRCh37Chr 5, 112177225: 112177228
6APCNM_ 000038.5(APC): c.637C> T (p.Arg213Ter)SNVPathogenicrs587781392GRCh37Chr 5, 112116592: 112116592
7APCNM_ 000038.5(APC): c.220+2T> ASNVLikely pathogenicrs587781809GRCh37Chr 5, 112102109: 112102109
8APCNM_ 000038.5(APC): c.2004delC (p.Leu669Terfs)deletionPathogenicrs587782303GRCh37Chr 5, 112173295: 112173295
9APCNM_ 000038.5(APC): c.426_ 427delAT (p.Leu143Alafs)deletionPathogenicrs587782557GRCh37Chr 5, 112111329: 112111330
10APCNM_ 000038.5(APC): c.3286C> T (p.Gln1096Ter)SNVPathogenicrs587783029GRCh38Chr 5, 112838880: 112838880
11APCNM_ 000038.5(APC): c.2107delG (p.Ala703Glnfs)deletionPathogenicrs587783030GRCh38Chr 5, 112837701: 112837701
12APCNM_ 000038.5(APC): c.4666delA (p.Thr1556Leufs)deletionPathogenicrs587783031GRCh38Chr 5, 112840260: 112840260
13APCNM_ 000038.5(APC): c.3814delT (p.Ser1272Glnfs)deletionPathogenicrs587783033GRCh38Chr 5, 112839408: 112839408
14APCNM_ 000038.5(APC): c.1744-2A> GSNVPathogenicrs587783035GRCh38Chr 5, 112834949: 112834949
15APCNC_ 000005.10: g.(?_ 112754891)_ (112844071_ ?)deldeletionPathogenicGRCh37Chr 5, 112090588: 112179768
16APCNM_ 000038.5(APC): c.4255delA (p.Ser1419Alafs)deletionLikely pathogenicrs727504420GRCh37Chr 5, 112175546: 112175546
17APCNM_ 000038.5(APC): c.477delC (p.Tyr159Terfs)deletionPathogenicrs730880250GRCh37Chr 5, 112111380: 112111380
18APCNM_ 000038.5(APC): c.1312+3_ 1312+4delATdeletionPathogenicrs730881228GRCh38Chr 5, 112819347: 112819348
19APCNM_ 000038.5(APC): c.1987C> T (p.Gln663Ter)SNVPathogenicrs730881240GRCh37Chr 5, 112173278: 112173278
20APCNM_ 000038.5(APC): c.5490_ 5493delTGAA (p.Asn1830Lysfs)deletionPathogenicrs730881273GRCh38Chr 5, 112841084: 112841087
21APCNM_ 000038.5(APC): c.3149delC (p.Ala1050Glufs)deletionPathogenicrs730882135GRCh38Chr 5, 112838743: 112838743
22APCNM_ 000038.5(APC): c.221-2A> GSNVPathogenic/ Likely pathogenicrs786201291GRCh37Chr 5, 112102884: 112102884
23APCNM_ 000038.5(APC): c.70C> T (p.Arg24Ter)SNVPathogenic/ Likely pathogenicrs145945630GRCh37Chr 5, 112090657: 112090657
24APCNM_ 000038.5(APC): c.994C> T (p.Arg332Ter)SNVPathogenicrs775126020GRCh37Chr 5, 112154723: 112154723
25APCNM_ 000038.5(APC): c.847C> T (p.Arg283Ter)SNVPathogenicrs786201856GRCh37Chr 5, 112151204: 112151204
26APCNM_ 000038.5(APC): c.3471_ 3474delGAGA (p.Glu1157Aspfs)deletionPathogenicrs786203020GRCh37Chr 5, 112174762: 112174765
27APCNM_ 000038.5(APC): c.925G> T (p.Gly309Ter)SNVPathogenicrs786204118GRCh37Chr 5, 112151282: 112151282
28APCNM_ 000038.5(APC): c.3830T> G (p.Leu1277Ter)SNVPathogenicrs786204169GRCh37Chr 5, 112175121: 112175121
29APCNM_ 000038.5(APC): c.4175C> A (p.Ser1392Ter)SNVPathogenicrs786204170GRCh37Chr 5, 112175466: 112175466
30APCNM_ 000038.5(APC): c.1262G> A (p.Trp421Ter)SNVPathogenicrs559510809GRCh38Chr 5, 112819294: 112819294
31APCNM_ 000038.5(APC): c.2563_ 2564delGA (p.Glu855Thrfs)deletionPathogenicrs794727160GRCh37Chr 5, 112173854: 112173855
32APCNM_ 000038.5(APC): c.4348C> T (p.Arg1450Ter)SNVPathogenic/ Likely pathogenicrs121913332GRCh37Chr 5, 112175639: 112175639
33APCNM_ 000038.5(APC): c.1072C> T (p.Gln358Ter)SNVPathogenicrs863224455GRCh38Chr 5, 112819104: 112819104
34APCNM_ 000038.5(APC): c.1409-?_ *(1_ ?)deldeletionPathogenicGRCh38Chr 5, 112827108: 112844127
35APCNM_ 000038.5(APC): c.2626C> T (p.Arg876Ter)SNVPathogenic/ Likely pathogenicrs121913333GRCh38Chr 5, 112838220: 112838220
36APCNM_ 000038.5(APC): c.3921_ 3924delAAAA (p.Ile1307Metfs)deletionPathogenicrs863224457GRCh38Chr 5, 112839515: 112839518
37APCNM_ 000038.5(APC): c.423G> T (p.Arg141Ser)SNVPathogenicrs863224458GRCh37Chr 5, 112111326: 112111326
38APCNM_ 000038.5(APC): c.791delA (p.Gly265Glufs)deletionPathogenicrs863224459GRCh37Chr 5, 112137037: 112137037
39APCNM_ 000038.5(APC): c.1886dupT (p.Leu629Phefs)duplicationPathogenicrs863224817GRCh38Chr 5, 112835093: 112835093
40APCNM_ 000038.5(APC): c.453delA (p.Glu152Lysfs)deletionPathogenicrs863224820GRCh38Chr 5, 112775659: 112775659
41APCNM_ 000038.5(APC): c.1312+3A> GSNVPathogenic/ Likely pathogenicrs863225311GRCh38Chr 5, 112819347: 112819347
42APCNM_ 000038.5(APC): c.1658G> A (p.Trp553Ter)SNVPathogenicrs863225318GRCh38Chr 5, 112828887: 112828887
43APCNM_ 000038.5(APC): c.1892_ 1904delTTATTGAAAGTGGinsAAT (p.Ile631Lysfs)indelPathogenic/ Likely pathogenicrs863225319GRCh38Chr 5, 112835099: 112835111
44APCNM_ 000038.5(APC): c.1972_ 1975delGAGA (p.Glu658Thrfs)deletionPathogenicrs863225322GRCh38Chr 5, 112837566: 112837569
45APCNM_ 000038.5(APC): c.2804dupA (p.Tyr935Terfs)duplicationPathogenic/ Likely pathogenicrs863225332GRCh38Chr 5, 112838398: 112838398
46APCNM_ 000038.5(APC): c.3298_ 3301delTCTC (p.Ser1100Hisfs)deletionPathogenic/ Likely pathogenicrs863225341GRCh37Chr 5, 112174589: 112174592
47APCNM_ 000038.5(APC): c.3785dupA (p.Tyr1262Terfs)duplicationLikely pathogenicrs863225345GRCh38Chr 5, 112839379: 112839379
48APCNM_ 000038.5(APC): c.423-?_ 531+?deldeletionPathogenic
49APCNM_ 000038.5(APC): c.5145delC (p.Asp1715Glufs)deletionPathogenicrs863225363GRCh38Chr 5, 112840739: 112840739
50APCNM_ 000038.5(APC): c.5804dupA (p.Ser1936Valfs)duplicationPathogenic/ Likely pathogenicrs863225367GRCh38Chr 5, 112841398: 112841398
51APCNM_ 000038.5(APC): c.645+1G> ASNVPathogenic/ Likely pathogenicrs863225370GRCh38Chr 5, 112780904: 112780904
52APCNM_ 000038.5(APC): c.3404_ 3405delAT (p.Tyr1135Terfs)deletionPathogenicrs864622086GRCh38Chr 5, 112838998: 112838999
53APCNM_ 000038.5(APC): c.3595_ 3596delAA (p.Lys1199Glufs)deletionPathogenicrs864622106GRCh38Chr 5, 112839189: 112839190
54APCNM_ 000038.5(APC): c.5826_ 5829delCAGA (p.Asp1942Glufs)deletionPathogenicrs864622228GRCh38Chr 5, 112841420: 112841423
55APCNM_ 000038.5(APC): c.481C> T (p.Gln161Ter)SNVPathogenicrs876658325GRCh37Chr 5, 112111384: 112111384
56APCNM_ 000038.5(APC): c.221-1G> CSNVLikely pathogenicrs863225327GRCh37Chr 5, 112102885: 112102885
57APCNM_ 000038.5(APC): c.220G> T (p.Glu74Ter)SNVPathogenic/ Likely pathogenicrs876658941GRCh37Chr 5, 112102107: 112102107
58APCNM_ 000038.5(APC): c.3925_ 3928delGAAA (p.Glu1309Argfs)deletionPathogenicrs876659647GRCh37Chr 5, 112175216: 112175219
59APCNM_ 000038.5(APC): c.531+1G> CSNVPathogenic/ Likely pathogenicrs876659973GRCh37Chr 5, 112111435: 112111435
60APCNM_ 000038.5(APC): c.4717delG (p.Glu1573Lysfs)deletionPathogenicrs878853217GRCh38Chr 5, 112840311: 112840311
61APCNM_ 000038.5(APC): c.-85_ *2113deldeletionPathogenicGRCh38Chr 5, 112737859: 112846239
62APCNM_ 000038.5(APC): c.1743+1G> ASNVLikely pathogenicrs761458613GRCh37Chr 5, 112164670: 112164670
63APCNM_ 000038.5(APC): c.1866_ 1867delCCinsAT (p.Tyr622Ter)indelPathogenicrs878853419GRCh37Chr 5, 112170770: 112170771
64APCNM_ 000038.5(APC): c.1875_ 1878delGACA (p.Asn627Leufs)deletionPathogenicrs878853420GRCh37Chr 5, 112170779: 112170782
65APCNM_ 000038.5(APC): c.2031_ 2034delCAGT (p.Ser678Metfs)deletionPathogenicrs878853422GRCh37Chr 5, 112173322: 112173325
66APCNM_ 000038.5(APC): c.2314delA (p.Thr772Leufs)deletionPathogenicrs878853426GRCh37Chr 5, 112173605: 112173605
67APCNM_ 000038.5(APC): c.249delT (p.Gly84Glufs)deletionPathogenicrs878853428GRCh37Chr 5, 112102914: 112102914
68APCNM_ 000038.5(APC): c.2795C> G (p.Ser932Ter)SNVPathogenicrs878853432GRCh37Chr 5, 112174086: 112174086
69APCNM_ 000038.5(APC): c.3196delA (p.Arg1066Aspfs)deletionPathogenicrs878853436GRCh37Chr 5, 112174487: 112174487
70APCNM_ 000038.5(APC): c.3340C> T (p.Arg1114Ter)SNVPathogenic/ Likely pathogenicrs121913331GRCh38Chr 5, 112838934: 112838934
71APCNM_ 000038.5(APC): c.3391C> T (p.Gln1131Ter)SNVPathogenicrs878853438GRCh37Chr 5, 112174682: 112174682
72APCNM_ 000038.5(APC): c.448A> T (p.Lys150Ter)SNVPathogenicrs878853444GRCh38Chr 5, 112775654: 112775654
73APCNM_ 000038.5(APC): c.4701delA (p.Asp1568Metfs)deletionPathogenicrs878853449GRCh38Chr 5, 112840295: 112840295
74APCNM_ 000038.5(APC): c.476dupA (p.Tyr159Terfs)duplicationPathogenic/ Likely pathogenicrs878853451GRCh37Chr 5, 112111379: 112111379
75APCNM_ 000038.5(APC): c.4987G> T (p.Glu1663Ter)SNVPathogenicrs758987855GRCh37Chr 5, 112176278: 112176278
76APCNM_ 000038.5(APC): c.5025dupT (p.Arg1676Terfs)duplicationPathogenicrs878853454GRCh37Chr 5, 112176316: 112176316
77APCNM_ 000038.5(APC): c.5917delA (p.Ser1973Valfs)deletionPathogenicrs878853458GRCh37Chr 5, 112177208: 112177208
78APCNM_ 000038.5(APC): c.595dupG (p.Ala199Glyfs)duplicationPathogenicrs878853459GRCh37Chr 5, 112116550: 112116550
79APCNM_ 000038.5(APC): c.6610C> T (p.Arg2204Ter)SNVLikely pathogenicrs752654519GRCh38Chr 5, 112842204: 112842204
80APCNM_ 000038.5(APC): c.934-?_ *2113+?deldeletionPathogenic
81APCNM_ 001127511.2(APC): c.-191T> CSNVPathogenicrs879253783GRCh38Chr 5, 112707527: 112707527
82APCNM_ 001127511.2(APC): c.-192A> GSNVPathogenicrs879253784GRCh38Chr 5, 112707526: 112707526
83APCNM_ 001127511.2(APC): c.-192A> TSNVPathogenicrs879253784GRCh38Chr 5, 112707526: 112707526
84APCNM_ 001127511.2(APC): c.-190G> ASNVPathogenicrs879253785GRCh38Chr 5, 112707528: 112707528
85APCNM_ 000038.5(APC): c.1239dupA (p.Arg414Thrfs)duplicationPathogenicrs879254088GRCh38Chr 5, 112819271: 112819271
86APCNM_ 000038.5(APC): c.422+2T> CSNVLikely pathogenicrs879254169GRCh37Chr 5, 112103089: 112103089
87APCNM_ 000038.5(APC): c.-18-?_ 834+?dupduplicationLikely pathogenic
88APCNM_ 000038.5(APC): c.2483delC (p.Thr828Ilefs)deletionPathogenicrs886042600GRCh38Chr 5, 112838077: 112838077
89APCNM_ 000038.5(APC): c.5952_ 5955delTGAA (p.Glu1985Leufs)deletionLikely pathogenicrs1057517544GRCh38Chr 5, 112841546: 112841549
90APCNM_ 000038.5(APC): c.3013_ 3019delGCCCATA (p.Ala1005Lysfs)deletionLikely pathogenicrs1057517553GRCh38Chr 5, 112838607: 112838613
91APCNM_ 000038.5(APC): c.3956delC (p.Pro1319Leufs)deletionPathogenicrs1057517558GRCh37Chr 5, 112175247: 112175247
92APCNM_ 000038.5(APC): c.933+2T> CSNVLikely pathogenicrs1057517559GRCh38Chr 5, 112815595: 112815595
93APCNM_ 000038.5(APC): c.1548+2T> CSNVLikely pathogenicrs1057517561GRCh38Chr 5, 112827249: 112827249
94APCNM_ 000038.5(APC): c.6371T> A (p.Leu2124Ter)SNVLikely pathogenicrs1057517568GRCh37Chr 5, 112177662: 112177662
95APCNM_ 000038.5(APC): c.531+2dupTduplicationPathogenicGRCh38Chr 5, 112775739: 112775739
96APCNM_ 000038.5(APC): c.1742delA (p.Lys581Argfs)deletionPathogenicrs1060503259GRCh38Chr 5, 112828971: 112828971
97APCNM_ 000038.5(APC): c.874_ 880delTTGAGTT (p.Ser293Valfs)deletionPathogenicrs1060503263GRCh38Chr 5, 112815534: 112815540
98APCNM_ 000038.5(APC): c.1759dupA (p.Ser587Lysfs)duplicationPathogenicGRCh38Chr 5, 112834966: 112834966
99APCNM_ 000038.5(APC): c.1744-11_ 1744-1deldeletionLikely pathogenicGRCh38Chr 5, 112834940: 112834950
100APCNM_ 000038.5(APC): c.2795C> A (p.Ser932Ter)SNVPathogenicrs878853432GRCh38Chr 5, 112838389: 112838389
101APCNM_ 000038.5(APC): c.2240C> G (p.Ser747Ter)SNVPathogenicrs773020689GRCh38Chr 5, 112837834: 112837834
102APCNM_ 000038.5(APC): c.2097G> A (p.Trp699Ter)SNVPathogenicrs1060503282GRCh37Chr 5, 112173388: 112173388
103APCNM_ 000038.5(APC): c.2635C> T (p.Gln879Ter)SNVPathogenicrs1060503287GRCh38Chr 5, 112838229: 112838229
104APCNM_ 000038.5(APC): c.1409-5A> GSNVLikely pathogenicrs768109346GRCh38Chr 5, 112827103: 112827103
105APCNM_ 000038.5(APC): c.1312+5G> ASNVLikely pathogenicrs886039507GRCh38Chr 5, 112819349: 112819349
106APCNM_ 000038.5(APC): c.3827C> A (p.Ser1276Ter)SNVPathogenicrs1060503299GRCh38Chr 5, 112839421: 112839421
107APCNM_ 000038.5(APC): c.14C> A (p.Ser5Ter)SNVPathogenicrs373718658GRCh38Chr 5, 112754904: 112754904
108APCNM_ 000038.5(APC): c.2098delG (p.Asp700Thrfs)deletionPathogenicrs1060503305GRCh38Chr 5, 112837692: 112837692
109APCNM_ 000038.5(APC): c.2910_ 2911delTG (p.Ser970Argfs)deletionPathogenicrs1060503307GRCh38Chr 5, 112838504: 112838505
110APCNM_ 000038.5(APC): c.2309C> G (p.Ser770Ter)SNVPathogenicrs1060503310GRCh38Chr 5, 112837903: 112837903
111APCNM_ 000038.5(APC): c.1958G> T (p.Arg653Met)SNVLikely pathogenicrs1060503318GRCh38Chr 5, 112835165: 112835165
112APCNM_ 000038.5(APC): c.2133delT (p.His712Ilefs)deletionPathogenicrs1060503321GRCh38Chr 5, 112837727: 112837727
113APCNM_ 000038.5(APC): c.532-8G> ASNVLikely pathogenicrs1060503323GRCh38Chr 5, 112780782: 112780782
114APCNM_ 000038.5(APC): c.6247_ 6250delATACinsTGT (p.Ile2083Cysfs)indelLikely pathogenicGRCh37Chr 5, 112177538: 112177541
115APCNM_ 000038.5(APC): c.3577_ 3578delCA (p.Gln1193Valfs)deletionPathogenicrs1060503326GRCh38Chr 5, 112839171: 112839172
116APCNM_ 000038.5(APC): c.3241_ 3242delAG (p.Ser1081Hisfs)deletionPathogenicrs1060503327GRCh38Chr 5, 112838835: 112838836
117APCNM_ 000038.5(APC): c.471G> A (p.Trp157Ter)SNVPathogenicrs1060503328GRCh38Chr 5, 112775677: 112775677
118APCNM_ 000038.5(APC): c.1370C> G (p.Ser457Ter)SNVPathogenicrs1060503333GRCh38Chr 5, 112821953: 112821953
119APCNM_ 000038.5(APC): c.761C> G (p.Ser254Ter)SNVPathogenicrs1060503334GRCh38Chr 5, 112801310: 112801310
120APCNM_ 000038.5(APC): c.2096G> A (p.Trp699Ter)SNVPathogenicrs1060503336GRCh38Chr 5, 112837690: 112837690
121APCNM_ 000038.5(APC): c.1402G> T (p.Glu468Ter)SNVPathogenicrs1060503340GRCh38Chr 5, 112821985: 112821985
122APCNM_ 000038.5(APC): c.4357_ 4363delCCTAAAAinsAAT (p.Pro1453Asnfs)indelPathogenicGRCh38Chr 5, 112839951: 112839957
123APCNM_ 000038.5(APC): c.6976C> T (p.Arg2326Ter)SNVLikely pathogenicrs1060503355GRCh38Chr 5, 112842570: 112842570
124APCNM_ 000038.5(APC): c.1879_ 1882delAACA (p.Asn627Leufs)deletionPathogenicrs1060503360GRCh38Chr 5, 112835086: 112835089
125APCNM_ 000038.5(APC): c.3186_ 3187delAA (p.Ser1063Terfs)deletionPathogenicrs1060503362GRCh37Chr 5, 112174477: 112174478
126APCNM_ 000038.5(APC): c.3473_ 3474delGA (p.Arg1158Thrfs)deletionPathogenicrs1060503365GRCh38Chr 5, 112839067: 112839068
127APCNM_ 000038.5(APC): c.1246dupT (p.Tyr416Leufs)duplicationPathogenicGRCh38Chr 5, 112819278: 112819278
128APCNM_ 000038.5(APC): c.4404_ 4418delGCAAGCTGCAGTAAAinsC (p.Lys1468Asnfs)indelPathogenicGRCh38Chr 5, 112839998: 112840012
129APCNC_ 000005.10: g.(?_ 112818966)_ (112821991_ ?)deldeletionPathogenicGRCh38Chr 5, 112818966: 112821991
130APCNC_ 000005.10: g.(?_ 112754873)_ (112821991_ ?)dupduplicationLikely pathogenicGRCh37Chr 5, 112090570: 112157688
131APCNC_ 000005.10: g.(?_ 112780790)_ (112846239_ ?)deldeletionPathogenicGRCh38Chr 5, 112780790: 112846239
132APCNC_ 000005.10: g.(?_ 112815495)_ (112821991_ ?)deldeletionPathogenicGRCh38Chr 5, 112815495: 112821991
133APCNC_ 000005.10: g.(?_ 112737859)_ (112815593_ ?)deldeletionPathogenicGRCh37Chr 5, 112073556: 112151290
134APCNM_ 000038.5(APC): c.1917dupA (p.Arg640Thrfs)duplicationLikely pathogenicrs397515732GRCh37Chr 5, 112170821: 112170821
135APCNM_ 000038.5(APC): c.3162delC (p.His1054Glnfs)deletionPathogenicrs397515733GRCh37Chr 5, 112174453: 112174453
136APCNM_ 000038.5(APC): c.694C> T (p.Arg232Ter)SNVPathogenicrs397515734GRCh37Chr 5, 112128191: 112128191
137APCNM_ 000038.5(APC): c.896_ 897delCT (p.Ser299Cysfs)deletionPathogenicrs397515735GRCh37Chr 5, 112151253: 112151254
138APCNM_ 000038.5(APC): c.730_ 731delAG (p.Arg244Valfs)deletionPathogenicrs387906228GRCh37Chr 5, 112136976: 112136977
139APCNM_ 000038.5(APC): c.1369delT (p.Ser457Hisfs)deletionPathogenicrs387906229GRCh37Chr 5, 112157649: 112157649
140APCNM_ 000038.5(APC): c.1500T> G (p.Tyr500Ter)SNVPathogenicrs387906230GRCh37Chr 5, 112162896: 112162896
141APCNM_ 000038.5(APC): c.904C> T (p.Arg302Ter)SNVPathogenicrs137854568GRCh37Chr 5, 112151261: 112151261
142APCNM_ 000038.5(APC): c.839C> G (p.Ser280Ter)SNVPathogenicrs137854569GRCh37Chr 5, 112151196: 112151196
143APCNM_ 000038.5(APC): c.2138C> G (p.Ser713Ter)SNVPathogenicrs137854570GRCh37Chr 5, 112173429: 112173429
144APCNM_ 000038.5(APC): c.4012C> T (p.Gln1338Ter)SNVPathogenic/ Likely pathogenicrs121913327GRCh37Chr 5, 112175303: 112175303
145APCNM_ 000038.5(APC): c.509_ 512delATAG (p.Asp170Valfs)deletionPathogenicrs387906231GRCh37Chr 5, 112111412: 112111415
146APCNM_ 000038.5(APC): c.1069dupA (p.Ile357Asnfs)duplicationPathogenicrs387906232GRCh37Chr 5, 112154798: 112154798
147APCNM_ 000038.5(APC): c.1621C> T (p.Gln541Ter)SNVPathogenicrs137854572GRCh37Chr 5, 112163698: 112163698
148APCNM_ 000038.5(APC): c.1660C> T (p.Arg554Ter)SNVPathogenicrs137854573GRCh37Chr 5, 112164586: 112164586
149APCNM_ 000038.5(APC): c.1690C> T (p.Arg564Ter)SNVPathogenicrs137854574GRCh37Chr 5, 112164616: 112164616
150APCNM_ 000038.5(APC): c.1885_ 1886insA (p.Leu629Tyrfs)insertionPathogenicrs387906233GRCh37Chr 5, 112170789: 112170790
151APCNM_ 000038.5(APC): c.2805C> A (p.Tyr935Ter)SNVPathogenicrs137854575GRCh37Chr 5, 112174096: 112174096
152APCNM_ 000038.5(APC): c.4393_ 4394delAG (p.Ser1465Trpfs)deletionPathogenicrs387906234GRCh37Chr 5, 112175684: 112175685
153APCNM_ 000038.5(APC): c.4391_ 4394delAGAG (p.Glu1464Valfs)deletionPathogenicrs387906235GRCh37Chr 5, 112175682: 112175685
154APCNM_ 000038.5(APC): c.470G> A (p.Trp157Ter)SNVPathogenicrs137854576GRCh37Chr 5, 112111373: 112111373
155APCNM_ 000038.5(APC): c.643C> T (p.Gln215Ter)SNVPathogenicrs137854577GRCh37Chr 5, 112116598: 112116598
156APCNC_ 000005.10: g.112836913_ 112908314del71402deletionPathogenicGRCh37Chr 5, 112172610: 112244011
157APCNM_ 000038.5(APC): c.3927_ 3931delAAAGA (p.Glu1309Aspfs)deletionPathogenicrs121913224GRCh37Chr 5, 112175218: 112175222
158APCNM_ 000038.5(APC): c.5942delA (p.Asn1981Ilefs)deletionPathogenicrs397509433GRCh37Chr 5, 112177233: 112177233
159APCNM_ 000038.5(APC): c.5582_ 5585delCTTT (p.Ser1861Terfs)deletionPathogenicrs587776520GRCh38Chr 5, 112841176: 112841179
160APCNM_ 000038.5(APC): c.4611_ 4612delAG (p.Glu1538Ilefs)deletionPathogenicrs387906236GRCh37Chr 5, 112175902: 112175903
161APCNM_ 000038.5(APC): c.1495C> T (p.Arg499Ter)SNVPathogenicrs137854580GRCh37Chr 5, 112162891: 112162891
162APCAPC, TYR486TERSNVPathogenic
163APCNM_ 000038.5(APC): c.1311_ 1312+1delAAGdeletionPathogenicrs397514030GRCh37Chr 5, 112155040: 112155042
164APCNM_ 000038.5(APC): c.1098_ 1099delCT (p.Ser367Cysfs)deletionPathogenicrs387906237GRCh37Chr 5, 112154827: 112154828
165APCNM_ 000038.5(APC): c.1192_ 1193delAA (p.Lys398Glufs)deletionPathogenicrs387906238GRCh37Chr 5, 112154921: 112154922
166APCNM_ 000038.5(APC): c.937_ 938delGA (p.Glu313Asnfs)deletionPathogenicrs387906239GRCh37Chr 5, 112154666: 112154667
167APCNM_ 000038.5(APC): c.2093T> A (p.Leu698Ter)SNVPathogenicrs137854582GRCh37Chr 5, 112173384: 112173384
168APCAPC deletiondeletionPathogenicGRCh38Chr 5, 112707504: 112846240
169APCNM_ 000038.5(APC): c.423-1G> ASNVPathogenicrs397514031GRCh37Chr 5, 112111325: 112111325
170APCAPC, 11-BP INS, NT1060insertionPathogenic
171APCNM_ 000038.5(APC): c.622C> T (p.Gln208Ter)SNVPathogenicrs137854583GRCh37Chr 5, 112116577: 112116577
172APCNG_ 008481.4: g.(?_ 150033)_ (158719_ ?)deldeletionPathogenicGRCh38Chr 5, 112837553: 112846239
173APCAPC, 5-BP DEL, NT3221deletionPathogenic
174APCNM_ 000038.5(APC): c.3183_ 3187delACAAA (p.Gln1062Terfs)deletionPathogenicrs587779352GRCh37Chr 5, 112174474: 112174478
175APCNM_ 000038.5(APC): c.3202_ 3205delTCAA (p.Ser1068Glyfs)deletionPathogenicrs587779353GRCh37Chr 5, 112174493: 112174496
176APCNM_ 000038.5(APC): c.1659G> A (p.Trp553Ter)SNVPathogenicrs398123116GRCh37Chr 5, 112164585: 112164585
177APCNM_ 000038.5(APC): c.2365C> T (p.Gln789Ter)SNVPathogenicrs398123117GRCh37Chr 5, 112173656: 112173656
178APCNM_ 000038.5(APC): c.2547_ 2550delTAGA (p.Asp849Glufs)deletionPathogenicrs398123118GRCh37Chr 5, 112173838: 112173841
179APCNM_ 000038.5(APC): c.2731G> T (p.Glu911Ter)SNVPathogenicrs398123119GRCh37Chr 5, 112174022: 112174022
180APCNM_ 000038.5(APC): c.2805delC (p.Tyr935Terfs)deletionPathogenicrs398123120GRCh37Chr 5, 112174096: 112174096
181APCNM_ 000038.5(APC): c.3982C> T (p.Gln1328Ter)SNVPathogenicrs398123121GRCh37Chr 5, 112175273: 112175273
182APCNM_ 000038.5(APC): c.4473dupT (p.Ala1492Cysfs)duplicationPathogenicrs398123122GRCh37Chr 5, 112175764: 112175764

Expression for genes affiliated with Adenomatous Polyposis Coli

About this section
Search GEO for disease gene expression data for Adenomatous Polyposis Coli.

Pathways for genes affiliated with Adenomatous Polyposis Coli

About this section

Pathways related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show all 48)
idSuper pathwaysScoreTop Affiliating Genes
19.9APC, SPATA13
29.5CDH1, CTNNB1
39.5CDH1, CTNNB1
49.4APC, AXIN1, CTNNB1
59.4APC, CTNNB1, GSK3B
69.3AXIN1, CTNNB1, MAPRE1
7
Show member pathways
9.3APC, CDH1, CTNNB1
98.9APC, AXIN1, CTNNB1, GSK3B
10
Show member pathways
8.9APC, AXIN1, CTNNB1, GSK3B
118.9APC, AXIN1, CTNNB1, GSK3B
12
Show member pathways
8.9APC, AXIN1, AXIN2, CTNNB1
138.8APC, AXIN2, CTNNB1, GSK3B
148.8CTNNB1, GSK3B, MYC
15
Show member pathways
8.7APC, CDH1, CTNNB1, GSK3B
16
Show member pathways
8.7APC, CDH1, CTNNB1, GSK3B
17
Show member pathways
8.7APC, AXIN1, AXIN2, GSK3B
188.7CDH1, CTNNB1, MYC
198.7CDH1, CTNNB1, MYC
208.7AXIN1, GSK3B, MYC
21
Show member pathways
8.6AXIN1, AXIN2, CTNNB1, GSK3B
228.4CDH1, CTNNB1, MAPRE1, MAPRE2, MAPRE3
23
Show member pathways
8.4APC, AXIN1, AXIN2, CTNNB1, GSK3B
248.3APC, AXIN1, CDH1, CTNNB1, GSK3B
258.3APC, AXIN1, CDH1, CTNNB1, GSK3B
268.3APC, APC2, CTNNB1, GSK3B, MYC
27
Show member pathways
8.3APC, CDH1, GSK3B, MYC
28
Show member pathways
8.2CDH1, CTNNB1, GSK3B, MYC
29
Show member pathways
8.1APC, APC2, AXIN1, AXIN2, CTNNB1, GSK3B
308.1APC, AXIN1, CTNNB1, GSK3B, MYC
318.1APC, AXIN1, CTNNB1, GSK3B, MYC
328.1APC, AXIN1, CTNNB1, GSK3B, MYC
338.1APC, AXIN1, CTNNB1, GSK3B, MYC
34
Show member pathways
8.1AMER1, APC, AXIN1, AXIN2, CTNNB1, GSK3B
358.1AMER1, APC, AXIN1, AXIN2, CTNNB1, GSK3B
367.9APC, AXIN2, CDH1, CTNNB1, MYC
377.6APC, AXIN1, AXIN2, CTNNB1, GSK3B, MYC
387.5APC, AXIN1, CDH1, CTNNB1, GSK3B, MYC
397.4APC, AXIN2, CDH1, CTNNB1, GSK3B, MYC
40
Show member pathways
7.3APC, APC2, AXIN1, AXIN2, CTNNB1, GSK3B
417.3APC, APC2, AXIN1, AXIN2, CTNNB1, GSK3B
42
Show member pathways
7.3AMER1, APC, AXIN1, AXIN2, CTNNB1, GSK3B
437.2AXIN1, AXIN2, CDH1, CTNNB1, GSK3B, MYC
44
Show member pathways
7.2AMER1, APC, AXIN1, CDH1, CTNNB1, GSK3B
45
Show member pathways
6.7APC, APC2, AXIN1, AXIN2, CDH1, CTNNB1
46
Show member pathways
6.7APC, APC2, AXIN1, AXIN2, CDH1, CTNNB1
476.7APC, APC2, AXIN1, AXIN2, CDH1, CTNNB1
486.7APC, APC2, AXIN1, AXIN2, CDH1, CTNNB1

GO Terms for genes affiliated with Adenomatous Polyposis Coli

About this section

Cellular components related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1cell projection membraneGO:003125310.6CTNNB1, MAPRE1
2apical junction complexGO:004329610.3CDH1, CTNNB1
3flotillin complexGO:001660010.2CDH1, CTNNB1
4microtubule plus-endGO:003537110.1MAPRE1, MAPRE2, MAPRE3
5cell-cell adherens junctionGO:000591310.1APC, CDH1, CTNNB1
6microtubule cytoskeletonGO:00156309.8APC2, MAPRE1, MAPRE2, MAPRE3
7catenin complexGO:00163429.8APC, APC2, CDH1, CTNNB1
8lamellipodiumGO:00300279.6APC, CDH1, CTNNB1, SPATA13
9microtubuleGO:00058749.6APC, APC2, MAPRE1, MAPRE2, MAPRE3
10lateral plasma membraneGO:00163289.5APC, AXIN1, CDH1, CTNNB1
11Wnt signalosomeGO:19909099.4APC, CTNNB1, GSK3B
12centrosomeGO:00058139.3APC, AXIN2, CTNNB1, GSK3B, MAPRE1
13cytoskeletonGO:00058569.3APC, APC2, CTNNB1, MAPRE1, MAPRE2, MAPRE3
14beta-catenin destruction complexGO:00308779.2APC, AXIN1, AXIN2, CTNNB1, GSK3B
15perinuclear region of cytoplasmGO:00484718.3APC, APC2, AXIN1, CDH1, CTNNB1, GSK3B
16cytoplasmGO:00057375.7AMER1, APC, APC2, AXIN1, AXIN2, CDH1

Biological processes related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show all 23)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of catenin import into nucleusGO:003541410.4APC2, AXIN2
2positive regulation of microtubule plus-end bindingGO:190303310.4MAPRE1, MAPRE3
3regulation of microtubule-based processGO:003288610.3APC, GSK3B
4cellular response to indole-3-methanolGO:007168110.2CDH1, CTNNB1
5entry of bacterium into host cellGO:003563510.2CDH1, CTNNB1
6negative regulation of Wnt signaling pathwayGO:003017810.2APC, APC2, AXIN1
7positive regulation of peptidyl-threonine phosphorylationGO:001080010.2AXIN1, GSK3B
8regulation of centromeric sister chromatid cohesionGO:007060210.2AXIN2, CTNNB1
9protein localization to microtubuleGO:003537210.2GSK3B, MAPRE1
10positive regulation of mesenchymal cell proliferationGO:000205310.0CTNNB1, MYC
11positive regulation of protein catabolic processGO:004573210.0APC, AXIN1, GSK3B
12positive regulation of canonical Wnt signaling pathwayGO:00902639.9AMER1, AXIN1, AXIN2
13re-entry into mitotic cell cycleGO:00003209.7GSK3B, MYC
14beta-catenin destruction complex assemblyGO:19048859.7AMER1, APC, AXIN1, GSK3B
15beta-catenin-TCF complex assemblyGO:19048379.5AXIN2, CTNNB1, MYC
16beta-catenin destruction complex disassemblyGO:19048869.3AMER1, APC, AXIN1, CTNNB1, GSK3B
17proteasome-mediated ubiquitin-dependent protein catabolic processGO:00431619.3AMER1, APC, AXIN1, CTNNB1, GSK3B
18protein deubiquitinationGO:00165799.0APC, AXIN1, AXIN2, MYC
19negative regulation of canonical Wnt signaling pathwayGO:00900908.9AMER1, APC, APC2, AXIN1, AXIN2, GSK3B
20cell proliferationGO:00082838.9AXIN2, CTNNB1, MAPRE1, MAPRE2, MYC
21canonical Wnt signaling pathwayGO:00600708.8APC, AXIN1, CTNNB1, GSK3B, MYC
22positive regulation of transcription, DNA-templatedGO:00458938.5AXIN1, CDH1, CTNNB1, MAPRE3, MYC
23Wnt signaling pathwayGO:00160557.8AMER1, APC, APC2, AXIN1, AXIN2, CTNNB1

Molecular functions related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1microtubule plus-end bindingGO:005101010.7APC, MAPRE1
2gamma-catenin bindingGO:004529510.4APC, CDH1
3I-SMAD bindingGO:007041110.0AXIN1, AXIN2, CTNNB1
4microtubule bindingGO:00080179.7APC, APC2, MAPRE1, MAPRE2, MAPRE3
5cadherin bindingGO:00452969.7APC, CDH1, CTNNB1, MAPRE1
6identical protein bindingGO:00428029.5APC, AXIN1, MAPRE1, MAPRE2, MAPRE3
7protein kinase bindingGO:00199019.5APC, AXIN1, CTNNB1, GSK3B
8ubiquitin protein ligase bindingGO:00316258.7APC, AXIN1, AXIN2, GSK3B
9beta-catenin bindingGO:00080138.4AMER1, APC, APC2, AXIN1, AXIN2, CDH1
10protein bindingGO:00055155.7AMER1, APC, APC2, AXIN1, AXIN2, CDH1

Sources for Adenomatous Polyposis Coli

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet